Document Detail


Pathogenesis of haemophilic synovitis: clinical aspects.
MedLine Citation:
PMID:  17822514     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Arthropathy remains a major cause of morbidity in patients with haemophilia. Frequent bleeding into the joints leads to joint damage with resultant contractures, joint deformities and arthritis. This in turn leads to muscle atrophy, limited physical activity, osteoporosis and disability. Even though several studies of prophylactic factor replacement for persons with severe haemophilia demonstrate improved joint function, this therapy is still not readily available to most people with haemophilia around the world and a universal treatment protocol has not been used. In this article, we discuss key issues in the treatment of severe haemophilia: the optimal timing of initiation and termination of therapy, dosing options and goals of therapy. The options for countries where prophylaxis is not readily available are also discussed. Most studies are small and not randomized making consensus treatment recommendations difficult to formulate. Randomized, clinical trials are needed to provide the answers regarding the optimal treatment of patients with severe haemophilia.
Authors:
W K Hoots; N Rodriguez; L Boggio; L A Valentino
Related Documents :
21725634 - Flurbiprofen axetil enhances analgesic effect of fentanyl associated with increase in β...
21089194 - Slac wrist in the absence of recognised trauma and cppd.
21761014 - Data on repeated (131)i-wb scans and the incidence of positive tg and negative (131)i-w...
21619984 - Which troponometric best predicts midterm outcome after coronary artery bypass graft su...
20573274 - Monitoring for plasmodium falciparum drug resistance to artemisinin and artesunate in b...
7671924 - The long term prognosis of infective endocarditis.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Haemophilia : the official journal of the World Federation of Hemophilia     Volume:  13 Suppl 3     ISSN:  1351-8216     ISO Abbreviation:  Haemophilia     Publication Date:  2007 Nov 
Date Detail:
Created Date:  2007-09-07     Completed Date:  2008-02-25     Revised Date:  2009-10-21    
Medline Journal Info:
Nlm Unique ID:  9442916     Medline TA:  Haemophilia     Country:  England    
Other Details:
Languages:  eng     Pagination:  4-9     Citation Subset:  IM    
Affiliation:
Gulf States Haemophilia and Thrombophilia Center, The University of Texas Health Science Center, Houston, TX 77030, USA. keith.hoots@uth.tmc.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Age Factors
Cartilage, Articular
Child
Child, Preschool
Disease Management
Factor IX / therapeutic use
Factor VIII / therapeutic use
Female
Hemarthrosis / etiology*,  prevention & control
Hemophilia A / complications*,  drug therapy,  physiopathology
Humans
Male
Prospective Studies
Randomized Controlled Trials as Topic
Synovitis / complications,  drug therapy,  etiology*
Chemical
Reg. No./Substance:
9001-27-8/Factor VIII; 9001-28-9/Factor IX

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Haemophilic synovitis: basic concepts.
Next Document:  Pathogenesis of haemophilic synovitis: experimental studies on blood-induced joint damage.